Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 20:13:00 GMT 2025
by
admin
on
Tue Apr 01 20:13:00 GMT 2025
|
| Protein Type | RECEPTOR |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
TB2Q79LBS0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2628
Created by
admin on Tue Apr 01 20:13:00 GMT 2025 , Edited by admin on Tue Apr 01 20:13:00 GMT 2025
|
PRIMARY | |||
|
100000177280
Created by
admin on Tue Apr 01 20:13:00 GMT 2025 , Edited by admin on Tue Apr 01 20:13:00 GMT 2025
|
PRIMARY | |||
|
P11836
Created by
admin on Tue Apr 01 20:13:00 GMT 2025 , Edited by admin on Tue Apr 01 20:13:00 GMT 2025
|
PRIMARY | |||
|
TB2Q79LBS0
Created by
admin on Tue Apr 01 20:13:00 GMT 2025 , Edited by admin on Tue Apr 01 20:13:00 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_167 | 1_183 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
LIGAND->TARGET |
BINDING
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
LIGAND->TARGET |
BINDING
|
||
|
LIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.
|
||
|
LIGAND->TARGET |
BINDING
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
|
LIGAND->TARGET |
|
||
|
|
LIGAND->TARGET |
TRU-015 depletes B-cells from the peripheral blood in vitro, and can mediate complement-and antibody-dependent cellular cytotoxicity.
|
||
|
RADIOLIGAND->TARGET | |||
|
LIGAND->TARGET |
BINDING
|
||
|
INHIBITOR -> TARGET |
|
||
|
LIGAND->TARGET |
BINDING
|
||
|
CYTOTOXIC T-CELL->TARGET |
|
||
|
LIGAND->TARGET |
BINDING
|
||
|
|
ACTIVATOR -> TARGET |
CPO107 is to bind to CD20 on the target cell surface to induce the antibody-dependent cellmediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)
IN-VIVO
|
||
|
|
LIGAND->TARGET |
BINDING
|
||
|
|
CYTOTOXIC T-CELL->TARGET |
secrete interferon gamma in response to CD19 and CD20
expressing tumour cell lines
|
||
|
|
RADIOLIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
LIGAND->TARGET |
|
||
|
|
LIGAND->TARGET |
|
||
|
|
INHIBITOR -> TARGET |
IN-VITRO
|
||
|
|
ANTIGEN->TARGET |
|
||
|
|
CYTOTOXIC T-CELL->TARGET |
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET |
BINDING
|
||
|
|
LIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
LIGAND->TARGET |
|
||
|
LIGAND->TARGET |
|
||
|
|
LIGAND->TARGET |
|
||
|
|
LIGAND->TARGET |
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUTION | [1_36] [1_225] | SERINE | DEXFOSFOSERINE | VI4F0K069V | ||
| AMINO ACID SUBSTITUTION | [1_111] [1_220] | CYSTEINE |
Amount:
|
S-PALMITOYL CYSTEINE | 08WQ73S7SV | |
| AMINO ACID SUBSTITUTION | [1_239] | THREONINE | THREONINE PHOSPHATE | 3L4WX7B1EI |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|